Results 51 to 60 of about 26,226 (199)
Pathogenic PF4/Polyanion ELISA‐Negative Antibodies in HIT
American Journal of Hematology, Volume 101, Issue 8, Page 1790-1798, August 2026.ABSTRACT Background Platelet factor 4‐polyanion enzyme‐linked immunosorbent assays (ELISAs) are considered highly sensitive for diagnosing heparin‐induced thrombocytopenia (HIT), such that current practice guidelines recommend use of ELISA‐negative results to exclude HIT.
Adam J. Kanack +25 more
wiley +1 more source
Scientific ReportsCritically ill patients often need continuous renal replacement therapy (CRRT). This process can remove particles as large as 10 kDa, including medications such as fondaparinux.
Aleksander Aszkiełowicz +2 more
doaj +1 more source
Low Allergenic Potential With Fondaparinux: Results of a Prospective Investigation
, 2010 OBJECTIVE: To determine the incidence and causes of skin reactions to the synthetic pentasaccharide fondaparinux. PATIENTS AND METHODS: Patients who received prophylactic/therapeutic subcutaneous fondaparinux treatment for more than 7 days were ...
Marc Schindewolf +21 more
core +1 more source
An Italian cartography of VEXAS‐related thrombosis
HemaSphere, Volume 10, Issue 8, August 2026.Abstract Thrombotic events (TEs) occur in up to 40% of patients with vacuoles, E1 enzyme, X‐linked, autoinflammatory, and somatic (VEXAS) syndrome, but data on its clinical‐genomics features and anticoagulation strategies are limited. To gain more insight into this, we conducted a two‐step study evaluating the prevalence and outcome of TE in VEXAS ...
Giorgia Ranucci +42 more
wiley +1 more source
Arquivos Brasileiros de Cardiologia, 2016 Background: Recent studies have shown fondaparinux's superiority over enoxaparin in patients with non-ST elevation acute coronary syndrome (ACS), especially in relation to bleeding reduction.
Alexandre de Matos Soeiro +9 more
doaj +1 more source
Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis
, 2007 No data about the use of the pentasaccharide fondaparinux, a highly selective indirect inhibitor of factor Xa, in patients treated with haemodialysis are available.
Aregger, Fabienne +13 more
core +1 more source
The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.Abstract Ischemic stroke remains a leading cause of death and disability worldwide, and bleeding (particularly intracranial hemorrhage) continues to limit conventional antithrombotic therapy in secondary prevention, even with direct oral anticoagulants.
Federica Ferrari, Roberto Federico Villa
wiley +1 more source
Développement d’une forme orale du fondaparinux
, 2012 Since its introduction in the market in 2002, fondaparinux (Arixtra®) is a drug of choice in the anticoagulant therapy. Its structure corresponds to the heparin pentasaccharide sequence that mediates its interaction with the natural plasma inhibitor of ...
Ralay-Ranaivo, Bettina
core +2 more sources
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Simon Waigand +3 more
wiley +1 more source
Estimated impact of model‐guided venous thromboembolism prophylaxis versus real‐world practice
Journal of Hospital Medicine, Volume 21, Issue 8, Page 845-853, August 2026.Abstract Background The American Society of Hematology (ASH) recommends assessing venous thromboembolism (VTE) and major bleeding risk to optimize pharmacological VTE prophylaxis for medical inpatients. However, the clinical utility of model‐guided approaches remains unknown.
Benjamin G Mittman, Michael B. Rothberg
wiley +1 more source